State Street
TNGX icon

State Street’s Tango Therapeutics TNGX Stock Holding History

State Street’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187M Buy
5,979,806
+1,327,912
+29% +$32.8M 0.01% 1085
2026
Q1 		$97.3M Sell
4,651,894
-1,566,673
-25% -$21.8M ﹤0.01% 1387
2025
Q4 		$55.1M Buy
6,218,567
+2,853,362
+85% +$24.6M ﹤0.01% 1685
2025
Q3 		$28.3M Buy
3,365,205
+1,982,519
+143% +$13.4M ﹤0.01% 2051
2025
Q2 		$7.08M Buy
1,382,686
+238,243
+21% +$589K ﹤0.01% 2791
2025
Q1 		$1.57M Sell
1,144,443
-86,756
-7% -$213K ﹤0.01% 3324
2024
Q4 		$3.8M Sell
1,231,199
-1,087,009
-47% -$5.05M ﹤0.01% 3073
2024
Q3 		$17.9M Buy
2,318,208
+489,949
+27% +$4.68M ﹤0.01% 2274
2024
Q2 		$15.7M Sell
1,828,259
-1,037,839
-36% -$8.02M ﹤0.01% 2294
2024
Q1 		$22.8M Buy
2,866,098
+1,887,160
+193% +$20.2M ﹤0.01% 2137
2023
Q4 		$9.69M Buy
978,938
+25,059
+3% +$218K ﹤0.01% 2613
2023
Q3 		$10.7M Buy
953,879
+54,940
+6% +$335K ﹤0.01% 2554
2023
Q2 		$2.98M Buy
898,939
+77,410
+9% +$278K ﹤0.01% 3231
2023
Q1 		$3.25M Sell
821,529
-22,340
-3% -$130K ﹤0.01% 3149
2022
Q4 		$6.12M Sell
843,869
-28,733
-3% -$202K ﹤0.01% 2956
2022
Q3 		$3.16M Buy
872,602
+130,266
+18% +$556K ﹤0.01% 3273
2022
Q2 		$3.36M Buy
742,336
+495,202
+200% +$3M ﹤0.01% 3293
2022
Q1 		$1.87M Buy
247,134
+17,141
+7% +$149K ﹤0.01% 3594
2021
Q4 		$2.52M Buy
229,993
+31,893
+16% +$384K ﹤0.01% 3573
2021
Q3 		$2.56M Buy
+198,100
New +$2.37M ﹤0.01% 3542

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street's TNGX Position: Q2 2026 in Review

State Street increased its Tango Therapeutics (TNGX) stake by 29% in Q2 2026, buying an estimated $32.8M and bringing the position to 5,979,806 shares worth $187M. The position accounts for 0.01% of the portfolio, ranked #1085.

State Street first reported a position in TNGX in Q3 2021 and has held it in 20 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • State Street held 5,979,806 shares of Tango Therapeutics worth $187M as of Q2 2026.
  • State Street bought 1,327,912 Tango Therapeutics shares in Q2 2026, an estimated $32.8M.
  • Tango Therapeutics made up 0.01% of State Street's portfolio in Q2 2026, its #1085 holding.
  • State Street first reported a position in Tango Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.